
Simon Segars, chief executive of the UK chipmaker Arm Holdings, has said that he expects tough and protracted scrutiny from China over Nvidia’s $40bn takeover of the company, reported the Financial Times.
China’s chipmakers have urged Beijing to probe Nvidia’s proposed acquisition of Arm on the basis that it would hand the US company control over essential technology used in many of the world’s smartphones and data centres. That has led to concerns that regulators in China may not sign off the acquisition.
Speaking to the Financial Times on Tuesday, Mr Segars argued that the Chinese regulators would want to review the combination of Arm and Nvidia thoroughly, though he remained confident the deal would ultimately proceed. “It’s a tough place at the moment with geopolitics so we’ll have to play that very carefully,” he said, adding that regulatory clearance across all of its markets will “take a long time”.
The sale of Arm, which was bought by SoftBank in 2016, has led to a backlash in Britain over fears that the US technology giant could move the chipmaker, which is widely seen as the crown jewel of the UK’s technology industry, out of its headquarters in Cambridge.
The government could still ask the Competition and Markets Authority to review the transaction on “national security” grounds. Nvidia has made commitments to keep Arm in Cambridge and will spend £40m on a new supercomputer for Cambridge to ease concerns over the takeover.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas